Abivax (ABVX) Depreciation & Amortization (CF) (2025 - 2026)
Abivax's (ABVX) quarterly Depreciation & Amortization (CF) came in at $429663.7 in Q1 2026, up 49.62% year-on-year from $287164.5 in Q1 2025, and up 49.62% quarter-over-quarter from $287164.5 in Q1 2025.
Abivax (ABVX) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends
Abivax's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $429663.7 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - | 429,663.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 429,663.65 |
| Mar 31, 2026 | 429,663.65 |
| Mar 31, 2025 | 287,164.45 |
| Mar 31, 2025 | 287,164.45 |